JP2016104790A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104790A5
JP2016104790A5 JP2016006778A JP2016006778A JP2016104790A5 JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5 JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5
Authority
JP
Japan
Prior art keywords
protein
vector
tissue
dna encoding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016006778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016104790A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104790A publication Critical patent/JP2016104790A/ja
Publication of JP2016104790A5 publication Critical patent/JP2016104790A5/ja
Ceased legal-status Critical Current

Links

JP2016006778A 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬 Ceased JP2016104790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008119324 2008-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014019961A Division JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Publications (2)

Publication Number Publication Date
JP2016104790A JP2016104790A (ja) 2016-06-09
JP2016104790A5 true JP2016104790A5 (cg-RX-API-DMAC7.html) 2016-07-21

Family

ID=41255155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬
JP2016006778A Ceased JP2016104790A (ja) 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Country Status (10)

Country Link
US (1) US20110097309A1 (cg-RX-API-DMAC7.html)
EP (1) EP2301560A4 (cg-RX-API-DMAC7.html)
JP (3) JP5814549B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110027665A (cg-RX-API-DMAC7.html)
CN (1) CN102076351A (cg-RX-API-DMAC7.html)
AU (1) AU2009240885A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0911436A2 (cg-RX-API-DMAC7.html)
CA (1) CA2722906A1 (cg-RX-API-DMAC7.html)
RU (1) RU2010148785A (cg-RX-API-DMAC7.html)
WO (1) WO2009133940A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076351A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物
BRPI0911513A2 (pt) * 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
CN102076350A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 将骨髓来源的多能干细胞动员到末梢循环的药物
CN104825491A (zh) * 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
CN107188948B (zh) 2011-04-26 2021-11-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
CA2998410A1 (en) * 2015-09-14 2017-03-23 Universite Laval Anti-s100a8 for treating leukemia
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
CA3059544A1 (en) 2017-04-25 2018-11-01 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
EP3656850A4 (en) * 2017-07-18 2021-03-31 Shiseido Co., Ltd. MESENCHYMATIC STEM CELL INDUCTION AGENT
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院(同济大学附属东方医院) 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666A (zh) * 2025-09-22 2025-10-28 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU2001243288B2 (en) * 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
EP1390058A2 (en) * 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
AU2002311903A1 (en) * 2001-05-09 2002-11-18 University Hospitals Of Cleveland Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
JPWO2003043651A1 (ja) * 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤
EP1519957B1 (en) * 2002-07-03 2009-03-04 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004004770A1 (en) * 2002-07-05 2004-01-15 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
AU2004203732A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins
DE602004017148D1 (de) * 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
WO2006008779A1 (en) * 2004-07-20 2006-01-26 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata Use of hmgb1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
HUE035043T2 (en) * 2006-10-30 2018-05-02 Genomix Co Ltd A pharmaceutical composition for promoting functional regeneration of damaged tissue
CN102076350A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 将骨髓来源的多能干细胞动员到末梢循环的药物
BRPI0911513A2 (pt) * 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
CN102076351A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物

Similar Documents

Publication Publication Date Title
JP2016104790A5 (cg-RX-API-DMAC7.html)
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
BR112016029318A2 (pt) tratamento de mielomas
WO2015197598A3 (en) Multispecific antigen binding proteins
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MY189425A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
JP2017532302A5 (cg-RX-API-DMAC7.html)
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
CY1125513T1 (el) Προερχομενα απο λιπωδη ιστο στρωματικα αρχεγονα κυτταρα για χρηση σε αγωγη δυσαγωγων περιπλοκων περιπρωκτικων συριγγιων σε νοσο toy crohn
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA202091567A1 (ru) Химерные белки мти
JP2016516394A5 (cg-RX-API-DMAC7.html)
RU2021113516A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА